We also used the same PARP inhibitors at the same concentration (2 μM) in the BRCA1 mutant (HCC-1937, MDA-MB-436, and SUM-149PT) and BRCA2 mutant (HCC-1428) cell lines. This evidence concerns the gene PARP1 and hepatocellular carcinoma.